thioctic acid has been researched along with Ventricular Dysfunction, Left in 3 studies
Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bunsawat, K | 1 |
| Ratchford, SM | 1 |
| Alpenglow, JK | 1 |
| Park, SH | 1 |
| Jarrett, CL | 1 |
| Stehlik, J | 1 |
| Drakos, SG | 1 |
| Richardson, RS | 1 |
| Wray, DW | 1 |
| Hegazy, SK | 1 |
| Tolba, OA | 1 |
| Mostafa, TM | 1 |
| Eid, MA | 1 |
| El-Afify, DR | 1 |
| Kanorskiĭ, SG | 1 |
| Kanorskaia, IuS | 1 |
1 trial available for thioctic acid and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Alpha-lipoic acid improves subclinical left ventricular dysfunction in asymptomatic patients with type 1 diabetes.
Topics: Adolescent; Antioxidants; Child; Diabetes Mellitus, Type 1; Diabetic Cardiomyopathies; Female; Human | 2013 |
2 other studies available for thioctic acid and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Chronic antioxidant administration restores macrovascular function in patients with heart failure with reduced ejection fraction.
Topics: Aged; Antioxidants; Ascorbic Acid; Biomarkers; Case-Control Studies; Female; Heart Failure; Humans; | 2020 |
[Atrial fibrillation in patients with type 2 diabetes mellitus: specific features of development and antirecurrence therapy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Atrial Fi | 2010 |